The advent of pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, revolutionized the first-line treatment options for both patients with squamous and non-squamous NSCLC with programmed death ligand-1 (PD-L1) expression levels of ≥ 50%8. Here, PDCD1 is linked to non-small cell lung carcinoma.